Johnson & Johnson (NYSE: JNJ) is one of the most profitable US stocks to buy, with a price target raised to $208 from $193 by Bernstein. U.S. healthcare stocks are performing better, leading to a more favorable outlook for Johnson & Johnson in 2026. Stifel also raised the price target to $205 from $190, citing the recent acquisition of Halda Therapeutics.

The Halda acquisition is expected to impact Johnson & Johnson’s adjusted earnings per share by $0.20, with $0.10 in 2025 and 2026. The global healthcare company focuses on innovative medicines and medical technologies, serving a wide range of clients. While JNJ is a strong investment, there are AI stocks with greater potential and less downside risk, according to analysts.

For more insights on the best and worst Dow stocks and unstoppable stocks, check out related articles. Disclosure: None.

Read more at Yahoo Finance: Analysts Turn More Constructive on Johnson & Johnson (JNJ) Heading Into 2026